Significance of NF-kB targeting by bortezomib was validated in multiple myeloma cells where genes that belong to NF-kB pathway were significantly overexpressed in samples associated with response to bortezomib [3], [4]. The gene discussed is NFKB1; the disease is AL amyloidosis.